Advertisement
Advertisement
U.S. Markets close in 1 hr 29 mins
Advertisement
Advertisement
Advertisement
Advertisement

Daré Bioscience, Inc. (DARE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.9101-0.0152 (-1.64%)
As of 02:24PM EST. Market open.
Advertisement
Full screen
Loading interactive chart...
  • Zacks

    Dare Bioscience, Inc. (DARE) Upgraded to Buy: What Does It Mean for the Stock?

    Dare Bioscience, Inc. (DARE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • GlobeNewswire

    Daré Bioscience Announces Grant to Develop Novel Hydrogel Formulation for Delivery of Live Biotherapeutics to Support Vaginal Health

    Grant Funds Will Support Development of a Reconstitutable Vaginal Thermosetting Gel Formulation to Ultimately Serve as a Delivery Vehicle that Allows Administration of Live Biotherapeutics at the Point of Care in a Wide Range of Settings SAN DIEGO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it has received a grant from the Bill & Melinda Gates Foundation (the foundation) of $584,986 to support activities related

  • GlobeNewswire

    Daré Bioscience Announces Positive Topline Results from DARE-VVA1 Phase 1/2 Clinical Study

    DARE-VVA1 Demonstrated Improvement in Vaginal Cytology Parameters and Bothersome Symptoms of Vulvar and Vaginal Atrophy (VVA), Supporting Ongoing Development Investigational Therapy for Women with VVA Who Cannot, or Should Not, Take Supplemental Estrogen, Including Women with Hormone Receptor-Positive (HR+) Breast Cancer There are Currently No FDA-Approved Products Labeled for VVA Treatment for Patients with or at Risk of Recurrence of HR+ Breast Cancer SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE)

Advertisement
Advertisement